sales till june 2008

After reading the past company announcements i expect sales to be around $2million in the year ended june 2008 .This is for the sale of bioeffective A,B,R and ropren if approved, currently in the first quarter it was $65,000 based on sales of bioeffective A,B .
Companies in the sector normally trade on a PE of 25 and have a ebit/sales ratio of 25%. Based on $2 million in sales to june 2008 gives us a profit after tax of $350,000.
By june 2008 there will be 200million shares if not more, profit of $350,000 equates to EPS of .175 cents, PE of 25 gives us a fair value share price of 4.4cents (25*.175).
Lets say sales for the year ended june 2009 grow by 1000% to $20 million, profit after tax is around $3.5 million. Based on 200 million shares EPS is 1.75cents, PE of 25 gives us a fair value share price of 44 cents.
So using a sector average PE of 25 and a sector average ebit/sales ratio of 25 how much in sales is sla currently priced on, $58million in sales gives us a fair value share price of $1.25
So as you can see the stock price is factoring in sales many years away. not saying it wont get there but think current price is being inflated by management to get those unlisted options exercised and sold on the market at unjustified profits based on current and projected sales.